In fact, promising results on GLUT1 targeting, alone or in combination with conventional treatment, in a variety of tumor models are being described [53–55] and, based on the results from the present study, we anticipate pediatric adrenocortical carcinomas may also benefit from this therapeutic strategy. Here, SLC2A1 is linked to neoplasm.